These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 16468986)

  • 1. Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate.
    Hu G; Lin G; Wang M; Dick L; Xu RM; Nathan C; Li H
    Mol Microbiol; 2006 Mar; 59(5):1417-28. PubMed ID: 16468986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycobacterium tuberculosis prcBA genes encode a gated proteasome with broad oligopeptide specificity.
    Lin G; Hu G; Tsu C; Kunes YZ; Li H; Dick L; Parsons T; Li P; Chen Z; Zwickl P; Weich N; Nathan C
    Mol Microbiol; 2006 Mar; 59(5):1405-16. PubMed ID: 16468985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome.
    Hsu HC; Singh PK; Fan H; Wang R; Sukenick G; Nathan C; Lin G; Li H
    Biochemistry; 2017 Jan; 56(1):324-333. PubMed ID: 27976853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
    Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
    Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates.
    Lin G; Tsu C; Dick L; Zhou XK; Nathan C
    J Biol Chem; 2008 Dec; 283(49):34423-31. PubMed ID: 18829465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for the assembly and gate closure mechanisms of the Mycobacterium tuberculosis 20S proteasome.
    Li D; Li H; Wang T; Pan H; Lin G; Li H
    EMBO J; 2010 Jun; 29(12):2037-47. PubMed ID: 20461058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
    Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The persisting challenge of selective and specific proteasome inhibition.
    Groll M; Huber R; Moroder L
    J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914.
    Huber EM; Heinemeyer W; Groll M
    Structure; 2015 Feb; 23(2):407-17. PubMed ID: 25599643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.
    Groll M; Berkers CR; Ploegh HL; Ovaa H
    Structure; 2006 Mar; 14(3):451-6. PubMed ID: 16531229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
    Huber EM; Groll M
    Angew Chem Int Ed Engl; 2012 Aug; 51(35):8708-20. PubMed ID: 22711561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
    Kraus M; Rückrich T; Reich M; Gogel J; Beck A; Kammer W; Berkers CR; Burg D; Overkleeft H; Ovaa H; Driessen C
    Leukemia; 2007 Jan; 21(1):84-92. PubMed ID: 17024115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.
    Pekol T; Daniels JS; Labutti J; Parsons I; Nix D; Baronas E; Hsieh F; Gan LS; Miwa G
    Drug Metab Dispos; 2005 Jun; 33(6):771-7. PubMed ID: 15764713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
    Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
    J Cell Biochem; 2008 Jan; 103(1):270-83. PubMed ID: 17516511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.
    Xie SC; Gillett DL; Spillman NJ; Tsu C; Luth MR; Ottilie S; Duffy S; Gould AE; Hales P; Seager BA; Charron CL; Bruzzese F; Yang X; Zhao X; Huang SC; Hutton CA; Burrows JN; Winzeler EA; Avery VM; Dick LR; Tilley L
    J Med Chem; 2018 Nov; 61(22):10053-10066. PubMed ID: 30373366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic comparison of peptidic proteasome inhibitors highlights the α-ketoamide electrophile as an auspicious reversible lead motif.
    Stein ML; Cui H; Beck P; Dubiella C; Voss C; Krüger A; Schmidt B; Groll M
    Angew Chem Int Ed Engl; 2014 Feb; 53(6):1679-83. PubMed ID: 24403024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
    Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
    ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
    Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
    Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.